Early access

Let's talk about
your R environment.

Reprosia is in private early access. We work with a small number of pharma and biotech teams to build the right solution. No sales process — just a direct conversation about your needs.

Request early access
Tell us about your team and we'll be in touch within 48 hours.

Your information is used only to respond to your request. We do not share it with third parties. Data processed under EU GDPR within Belgium.

What to expect
01

We review your request

Within 48 hours, we'll review what you've shared and assess fit for early access.

02

An initial conversation

30 minutes with the founder. We'll understand your R environment, regulatory context, and what you're trying to solve.

03

Tailored platform demo

We'll show you Reprosia applied to your specific use case, not a generic product demo.

04

Early access onboarding

Selected teams get hands-on access with direct support from the Reprosia team throughout.

Email
For direct enquiries, partnership discussions, or press.
Open source
Explore reproducr and the full open-source package ecosystem.
GitHub
All open-source packages, issues, and contributions.
Location
Brussels, Belgium
ReproStats BV. EU data residency. GDPR compliant.
Frequently asked

Questions we
hear most often.

Is Reprosia available now? +
Reprosia is currently in private early access. We are working with a small number of pharma and biotech teams to refine the platform before a wider release. Submit a request and we'll assess fit and timeline together.
Do I need to migrate away from my existing R setup? +
No. Reprosia wraps around your existing R environment — your scripts, packages, and data pipelines stay where they are. We add the audit, validation, and submission layer on top, not instead of what you already have.
How does Reprosia handle sensitive clinical trial data? +
Reprosia is operated by ReproStats BV, a Belgian-registered entity. All data processing occurs within EU jurisdiction, GDPR compliant by default. We support on-premise deployment options for teams with strict data residency requirements. Clinical data never leaves your controlled environment unless you explicitly choose to share it.
Is the IQ/OQ/PQ documentation acceptable to FDA and EMA? +
Reprosia generates validation documentation aligned with FDA 21 CFR Part 11, EMA Annex 11, and GAMP 5 computer system validation guidance. The documentation format is designed to satisfy regulatory reviewers. That said, acceptability ultimately depends on your specific regulatory context and submission, and we recommend review by your regulatory affairs team.
Can Reprosia help with SAS to R migration? +
Yes. This is one of our core use cases. Reprosia provides automated equivalence testing between SAS and R outputs, migration audit trails documenting every difference and its justification, and a parallel validation period where both environments run simultaneously. The migration package is designed to produce agency-acceptable evidence of the transition.
How is Reprosia different from just using renv and git? +
renv and git are excellent tools and Reprosia builds on them. The difference is the regulatory layer: IQ/OQ/PQ documentation, 21 CFR Part 11-compliant audit trails, electronic signatures, risk scoring, drift detection across environments, ICH E9(R1) estimand documentation, and eCTD-ready submission packaging. renv locks your packages; Reprosia certifies your environment and produces the evidence that regulators require.
What is the relationship between Reprosia and ReproStats? +
ReproStats (reprostats.org) is the open-source project — four R packages (reproducr, regulog, lineager, estimandr) available on CRAN and GitHub. Reprosia is the enterprise platform built on that foundation, adding the AI audit engine, environment management, submission tooling, and enterprise workflows. Both are operated by ReproStats BV. The open-source packages remain free and will always be maintained independently.